Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer
Abstract
:1. Introduction
2. Results
2.1. Expression of Human Epidermal Growth Factor Receptor 2 (HER2)
2.2. Localization of HER2 Affibody-IR700Dye and Trastuzumab-Alexa488 Conjugates
2.3. The Morphological Effect by NIR-PIT
2.4. Cell Viability after Near-Infrared Photoimmunotherapy (NIR-PIT)
2.5. In Vivo Fluorescence Image
3. Discussion
4. Materials and Methods
4.1. Cell Culture
4.2. Immunocytochemistry (ICC)
4.3. Western Blotting Analysis
4.4. HER2 Affibody-IR700Dye Conjugate, Trastuzumab-IR700Dye or Alexa488 Conjugate
4.5. Confocal Microscopy Imaging of HER2 Affibody-IR700Dye and Trastuzumab-Alexa488 Conjugates
4.6. Flow Cytometry
4.7. Cell Viability Assay
4.8. Cell Images before and after Near-Infrared (NIR) Light Irradiation
4.9. Cell Apoptosis/Necrosis Assay
4.10. Near-Infrared Photoimmunotherapy (NIR-PIT) Illuminator
4.11. Animal Imaging
4.12. Immunohistochemistry
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
HER2 | Human epidermal growth factor receptor type 2 |
EGFR | Epidermal growth factor receptor |
NIR-PIT | Near-infrared photoimmunotherapy |
mAb | Monoclonal antibody |
ICC | Immunocytochemistry |
References
- Ross, J.S.; Slodkowska, E.A.; Symmans, W.F.; Pusztai, L.; Ravdin, P.M.; Hortobagyi, G.N. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine. Oncologist 2009, 14, 320–368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eroles, P.; Bosch, A.; Alejandro Pérez-Fidalgo, J.; Lluch, A. Molecular Biology in Breast Cancer: Intrinsic Subtypes and Signaling Pathways. Cancer Treat. Rev. 2012, 38, 698–707. [Google Scholar] [CrossRef] [PubMed]
- Meric-Bernstam, F.; Johnson, A.M.; Ileana Dumbrava, E.E.; Raghav, K.; Balaji, K.; Bhatt, M.; Murthy, R.K.; Rodon, J.; Piha-Paul, S.A. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities beyond Breast and Gastric Cancer. Clin. Cancer Res. 2019, 25, 2033–2041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yao, M.; Fu, P. Advances in Anti-HER2 Therapy in Metastatic Breast Cancer. Chin. Clin. Oncol. 2018, 7, 27. [Google Scholar] [CrossRef]
- Ahmed, S.; Sami, A.; Xiang, J. HER2-Directed Therapy: Current Treatment Options for HER2-Positive Breast Cancer. Breast Cancer 2015, 22, 101–116. [Google Scholar] [CrossRef]
- Pohlmann, P.R.; Mayer, I.A.; Mernaugh, R. Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res. 2009, 15, 7479–7491. [Google Scholar] [CrossRef] [Green Version]
- Mitsunaga, M.; Nakajima, T.; Sano, K.; Choyke, P.L.; Kobayashi, H. Near-Infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. Bioconj. Chem. 2012, 23, 604–609. [Google Scholar] [CrossRef] [Green Version]
- Nakajima, T.; Sato, K.; Hanaoka, H.; Watanabe, R.; Harada, T.; Choyke, P.L.; Kobayashi, H. The Effects of Conjugate and Light Dose on Photo-Immunotherapy Induced Cytotoxicity. BMC Cancer 2014, 14, 389. [Google Scholar] [CrossRef] [Green Version]
- Mitsunaga, M.; Ogawa, M.; Kosaka, N.; Rosenblum, L.T.; Choyke, P.L.; Kobayashi, H. Cancer Cell-Selective in Vivo near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules. Nat. Med. 2011, 17, 1685–1691. [Google Scholar] [CrossRef] [Green Version]
- Maruoka, Y.; Wakiyama, H.; Choyke, P.L.; Kobayashi, H. Near Infrared Photoimmunotherapy for Cancers: A Translational Perspective. EBioMedicine 2021, 70, 103501. [Google Scholar] [CrossRef]
- Löfblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Ståhl, S.; Frejd, F.Y. Affibody Molecules: Engineered Proteins for Therapeutic, Diagnostic and Biotechnological Applications. FEBS Lett. 2010, 584, 2670–2680. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ståhl, S.; Gräslund, T.; Eriksson Karlström, A.; Frejd, F.Y.; Nygren, P.Å.; Löfblom, J. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol. 2017, 35, 691–712. [Google Scholar] [CrossRef] [PubMed]
- Frejd, F.Y.; Kim, K.T. Affibody Molecules as Engineered Protein Drugs. Exp. Mol. Med. 2017, 49, e306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Orlova, A.; Feldwisch, J.; Abrahmsén, L.; Tolmachev, V. Update: Affibody Molecules for Molecular Imaging and Therapy for Cancer. Cancer Biother. Radiopharm. 2007, 22, 573–584. [Google Scholar] [CrossRef] [PubMed]
- Nilsson, F.Y.; Tolmachev, V. Affibody® Molecules: New Protein Domains for Molecular Imaging and Targeted Tumor Therapy. Curr. Opin. Drug Discov. Dev. 2007, 10, 167–175. [Google Scholar]
- Yamaguchi, H.; Pantarat, N.; Suzuki, T.; Evdokiou, A. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer. Int. J. Mol. Sci. 2019, 20, 5835. [Google Scholar] [CrossRef] [Green Version]
- Tanner, M.; Kapanen, A.I.; Junttila, T.; Raheem, O.; Grenman, S.; Elo, J.; Elenius, K.; Isola, J. Characterization of a Novel Cell Line Established from a Patient with Herceptin-Resistant Breast Cancer. Mol. Cancer Ther. 2004, 3, 1585–1592. [Google Scholar]
- Sato, K.; Ando, K.; Okuyama, S.; Moriguchi, S.; Ogura, T.; Totoki, S.; Hanaoka, H.; Nagaya, T.; Kokawa, R.; Takakura, H.; et al. Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Cent. Sci. 2018, 4, 1559–1569. [Google Scholar] [CrossRef] [Green Version]
- Eigenbrot, C.; Ultsch, M.; Dubnovitsky, A.; Abrahmsén, L.; Härd, T. Structural Basis for High-Affinity HER2 Receptor Binding by an Engineered Protein. Proc. Natl. Acad. Sci. USA 2010, 107, 15039–15044. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.B.; Hassan, M.; Fisher, R.; Chertov, O.; Chernomordik, V.; Kramer-Marek, G.; Gandjbakhche, A.; Capala, J. Affibody Molecules for in Vivo Characterization of HER2-Positive Tumors by near-Infrared Imaging. Clin. Cancer Res. 2008, 14, 3840–3849. [Google Scholar] [CrossRef] [Green Version]
- Nakajima, T.; Sano, K.; Choyke, P.L.; Kobayashi, H. Improving the Efficacy of Photoimmunotherapy (PIT) Using a Cocktail of Antibody Conjugates in a Multiple Antigen Tumor Model. Theranostics 2013, 3, 357–365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ito, K.; Mitsunaga, M.; Nishimura, T.; Kobayashi, H.; Tajiri, H. Combination Photoimmunotherapy with Monoclonal Antibodies Recognizing Different Epitopes of Human Epidermal Growth Factor Receptor 2: An Assessment of Phototherapeutic Effect Based on Fluorescence Molecular Imaging. Oncotarget 2016, 7, 14143–14152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Köninki, K.; Barok, M.; Tanner, M.; Staff, S.; Pitkänen, J.; Hemmilä, P.; Ilvesaro, J.; Isola, J. Multiple Molecular Mechanisms Underlying Trastuzumab and Lapatinib Resistance in JIMT-1 Breast Cancer Cells. Cancer Lett. 2010, 294, 211–219. [Google Scholar] [CrossRef] [PubMed]
- McCluskey, A.J.; Olive, A.J.; Starnbach, M.N.; Collier, R.J. Targeting HER2-Positive Cancer Cells with Receptor-Redirected Anthrax Protective Antigen. Mol. Oncol. 2013, 7, 440–451. [Google Scholar] [CrossRef] [PubMed]
- Xu, Y.; Bai, Z.; Huang, Q.; Pan, Y.; Pan, D.; Wang, L.; Yan, J.; Wang, X.; Yang, R.; Yang, M. PET of HER2 Expression with a Novel 18FAl Labeled Affibody. J. Cancer 2017, 8, 1170–1178. [Google Scholar] [CrossRef] [Green Version]
- McKnight, B.N.; Viola-Villegas, N.T. Monitoring Src Status after Dasatinib Treatment in HER2+ Breast Cancer with 89Zr-Trastuzumab PET Imaging. Breast Cancer Res. 2018, 20, 130. [Google Scholar] [CrossRef]
- Tominaga, N.; Kosaka, N.; Ono, M.; Katsuda, T.; Yoshioka, Y.; Tamura, K.; Lötvall, J.; Nakagama, H.; Ochiya, T. Brain Metastatic Cancer Cells Release MicroRNA-181c-Containing Extracellular Vesicles Capable of Destructing Blood-Brain Barrier. Nat. Commun. 2015, 6, 6716. [Google Scholar] [CrossRef] [Green Version]
- Dijkers, E.C.; Oude Munnink, T.H.; Kosterink, J.G.; Brouwers, A.H.; Jager, P.L.; de Jong, J.R.; van Dongen, G.A.; Schröder, C.P.; Lub-De Hooge, M.N.; de Vries, E.G. Biodistribution of 89 Zr-Trastuzumab and PET Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer. Clin. Pharmacol. Ther. 2010, 87, 586–592. [Google Scholar] [CrossRef]
- Burley, T.A.; Mączyńska, J.; Shah, A.; Szopa, W.; Harrington, K.J.; Boult, J.K.R.; Mrozek-Wilczkiewicz, A.; Vinci, M.; Bamber, J.C.; Kaspera, W.; et al. Near-Infrared Photoimmunotherapy Targeting EGFR—Shedding New Light on Glioblastoma Treatment. Int. J. Cancer 2018, 142, 2363–2374. [Google Scholar] [CrossRef] [Green Version]
- Ribeiro de Souza, A.L.; Marra, K.; Gunn, J.; Samkoe, K.S.; Hull, S.; Paulsen, K.D.; Pogue, B.W. Optimizing Glioma Detection Using an EGFR-Targeted Fluorescent Affibody. Photochem. Photobiol. 2018, 94, 1167–1171. [Google Scholar] [CrossRef]
- Tamura, K.; Kurihara, H.; Yonemori, K.; Tsuda, H.; Suzuki, J.; Kono, Y.; Honda, N.; Kodaira, M.; Yamamoto, H.; Yunokawa, M.; et al. 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. J. Nucl. Med. 2013, 54, 1869–1875. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Z.; Li, Y.; Chang, H.P.; Yu, X.; Shah, D.K. Two-Pore Physiologically Based Pharmacokinetic Model Validation Using Whole-Body Biodistribution of Trastuzumab and Different-Size Fragments in Mice. J. Pharmacokinet. Pharmacodyn. 2021, 48, 743–762. [Google Scholar] [CrossRef] [PubMed]
- Mączyńska, J.; da Pieve, C.; Burley, T.A.; Raes, F.; Shah, A.; Saczko, J.; Harrington, K.J.; Kramer-Marek, G. Immunomodulatory Activity of IR700-Labelled Affibody Targeting HER2. Cell Death Dis. 2020, 11, 886. [Google Scholar] [CrossRef] [PubMed]
- Hosseinimehr, S.J.; Tolmachev, V.; Orlova, A. Liver Uptake of Radiolabeled Targeting Proteins and Peptides: Considerations for Targeting Peptide Conjugate Design. Drug Discov. Today 2012, 17, 1224–1232. [Google Scholar] [CrossRef] [PubMed]
- Sörensen, J.; Sandberg, D.; Sandström, M.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Åström, G.; Lubberink, M.; Garske-Román, U.; Carlsson, J.; et al. First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule. J. Nucl. Med. 2014, 55, 730–735. [Google Scholar] [CrossRef] [Green Version]
- Sörensen, J.; Velikyan, I.; Sandberg, D.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Orlova, A.; Sandström, M.; Lubberink, M.; Olofsson, H.; et al. Measuring HER2-Receptor Expression in Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. Theranostics 2016, 6, 262–271. [Google Scholar] [CrossRef]
- Krasniqi, A.; D’Huyvetter, M.; Devoogdt, N.; Frejd, F.Y.; Sörensen, J.; Orlova, A.; Keyaerts, M.; Tolmachev, V. Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. J. Nucl. Med. 2018, 59, 85–891. [Google Scholar] [CrossRef] [Green Version]
- Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 Years of Image Analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yamaguchi, H.; On, J.; Morita, T.; Suzuki, T.; Okada, Y.; Ono, J.; Evdokiou, A. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. Int. J. Mol. Sci. 2021, 22, 12213. https://doi.org/10.3390/ijms222212213
Yamaguchi H, On J, Morita T, Suzuki T, Okada Y, Ono J, Evdokiou A. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. International Journal of Molecular Sciences. 2021; 22(22):12213. https://doi.org/10.3390/ijms222212213
Chicago/Turabian StyleYamaguchi, Haruka, Jotaro On, Takao Morita, Takamasa Suzuki, Yasuo Okada, Junya Ono, and Andreas Evdokiou. 2021. "Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer" International Journal of Molecular Sciences 22, no. 22: 12213. https://doi.org/10.3390/ijms222212213